UM  > Institute of Chinese Medical Sciences
Residential Collegefalse
Status已發表Published
Bilirubin Nanomedicines for the Treatment of Reactive Oxygen Species (ROS)-Mediated Diseases
Chen,Zhejie1; Vong,Chi Teng1; Gao,Caifang1; Chen,Shiyun1; Wu,Xu2; Wang,Shengpeng1; Wang,Yitao1
Source PublicationMolecular Pharmaceutics
ISSN1543-8384
2020-05-20
Abstract

Reactive oxygen species (ROS) are chemically reactive species that are produced in cellular aerobic metabolism. They mainly include superoxide anion, hydrogen peroxide, hydroxyl radicals, singlet oxygen, ozone, and nitric oxide and are implicated in many physiological and pathological processes. Bilirubin, a cardinal pigment in the bile, has been increasingly investigated to treat cancer, diabetes, ischemia-reperfusion injury, asthma, and inflammatory bowel diseases (IBD). Indeed, bilirubin has been shown to eliminate ROS production, so it is now considered as a promising therapeutic agent for ROS-mediated diseases and can be used for the development of antioxidative nanomedicines. This review summarizes the current knowledge of the physiological mechanisms of ROS production and its role in pathological changes and focuses on discussing the antioxidative effects of bilirubin and its application in the experimental studies of nanomedicines. Previous studies have shown that bilirubin was mainly used as a responsive molecule in the microenvironment of ROS overproduction in neoplastic tissues for the development of anticancer nanodrugs; however, it could also exert powerful ROS scavenging activity in chronic inflammation and ischemia-reperfusion injury. Therefore, bilirubin, as an inartificial ROS scavenger, is expected to be used for the development of nanomedicines against more diseases due to the universality of ROS involvement in human pathological conditions.

KeywordBilirubin Cancer Inflammation Nanoparticle Ros
Language英語English
DOI10.1021/acs.molpharmaceut.0c00337
URLView the original
Volume17
Issue7
Pages2260-2274
WOS IDWOS:000548455300004
WOS SubjectMedicine, Research & Experimental ; Pharmacology & Pharmacy
WOS Research AreaResearch & Experimental Medicine ; Pharmacology & Pharmacy
Indexed BySCIE
Scopus ID2-s2.0-85087529063
Fulltext Access
Citation statistics
Cited Times [WOS]:54   [WOS Record]     [Related Records in WOS]
Document TypeReview article
CollectionInstitute of Chinese Medical Sciences
THE STATE KEY LABORATORY OF QUALITY RESEARCH IN CHINESE MEDICINE (UNIVERSITY OF MACAU)
Corresponding AuthorWang,Shengpeng; Wang,Yitao
Affiliation1.State Key Laboratory of Quality Research in Chinese Medicine,Institute of Chinese Medical Sciences,University of Macau,999087,Macao
2.Laboratory of Molecular Pharmacology,Department of Pharmacology,Southwest Medical University,Luzhou,646000,China
First Author AffilicationInstitute of Chinese Medical Sciences
Corresponding Author AffilicationInstitute of Chinese Medical Sciences
Recommended Citation
GB/T 7714
Chen,Zhejie,Vong,Chi Teng,Gao,Caifang,et al. Bilirubin Nanomedicines for the Treatment of Reactive Oxygen Species (ROS)-Mediated Diseases[J]. Molecular Pharmaceutics, 2020, 17(7), 2260-2274.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Chen,Zhejie]'s Articles
[Vong,Chi Teng]'s Articles
[Gao,Caifang]'s Articles
Baidu academic
Similar articles in Baidu academic
[Chen,Zhejie]'s Articles
[Vong,Chi Teng]'s Articles
[Gao,Caifang]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Chen,Zhejie]'s Articles
[Vong,Chi Teng]'s Articles
[Gao,Caifang]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.